Views: 1,371 | Downloads:
22
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Clinical Experience of Sirolimus-Eluting Stents in Patients with Coronary Artery Disease at Bangkok Heart Institute
Lolekha P 
,
MD KB ,
Kukreja R ,
Mahanonda N ,
Numee M
,
MD KB ,
Kukreja R ,
Mahanonda N ,
Numee M KIERTIJAI BHURIPANYO, MD*,
NITHI MAHANONDA, MD*,
Drug eluting stents represent one of the fastest growing fields in interventional cardiology
today. From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson
&
Johnson)
appear to demonstrate a remarkable efficacy and safety in preventing restenosis.
From the present study, the authors reported clinical experience of SES in 40 consecutive
patients with coronary artery disease (CAD) between 25'h June and 11th October, 2002. The mean age
was 59
เธ‘
12.16 years (mean
เธ‘
SD) and 80 per cent of the patients were male. The majority of the
patients had chronic stable angina and most percutaneous coronary interventions were performed by
elective procedure (85% ). Thirty-five per cent of the patients had single vessel disease and 42.5 per
cent of the patients had double vessel disease. The authors successfully implanted 52 (69.3%) SES in
75 target lesions revascularization. Twenty-four (60%) of the patients had more than 1 vessel inter-
vention. Twenty-seven (67.5%) of the patients had complete revascularization by percutaneous coro-
nary intervention (PCI) and only 16 of 27 patients (59.3%) who had complete revascularization with
SES. The SES were usually implanted at middle part of the left anterior descending artery (MLAD)
( 11 lesions), proximal part of the left anterior descending artery (PLAD) (8 lesions), middle part of the
right coronary artery (MRCA) (8 lesions) and middle part of the left circumflex artery (MLCX) (6
lesions). The authors had to cover plaque entirely with SES, so SES implantation usually took longer
than the bare stent (BS). The authors followed the initial clinical outcome of the patients within 1
month after discharge. Few adverse clinical events were found during 1 month follow-up because SES
have a very low rate of restenosis in the short-term so, we have to follow-up the patients over a longer
period and will report the clinical outcome in the next study.
Key word
: Sirolimus Eluting-Stents, Clinical Experience, Outcome, Coronary Artery Disease
NITHI MAHANONDA, MD*,
Drug eluting stents represent one of the fastest growing fields in interventional cardiology
today. From a recent study, the sirolimus eluting stent (SES) (CYPHER, Cordis, Johnson
&
Johnson)
appear to demonstrate a remarkable efficacy and safety in preventing restenosis.
From the present study, the authors reported clinical experience of SES in 40 consecutive
patients with coronary artery disease (CAD) between 25'h June and 11th October, 2002. The mean age
was 59
เธ‘
12.16 years (mean
เธ‘
SD) and 80 per cent of the patients were male. The majority of the
patients had chronic stable angina and most percutaneous coronary interventions were performed by
elective procedure (85% ). Thirty-five per cent of the patients had single vessel disease and 42.5 per
cent of the patients had double vessel disease. The authors successfully implanted 52 (69.3%) SES in
75 target lesions revascularization. Twenty-four (60%) of the patients had more than 1 vessel inter-
vention. Twenty-seven (67.5%) of the patients had complete revascularization by percutaneous coro-
nary intervention (PCI) and only 16 of 27 patients (59.3%) who had complete revascularization with
SES. The SES were usually implanted at middle part of the left anterior descending artery (MLAD)
( 11 lesions), proximal part of the left anterior descending artery (PLAD) (8 lesions), middle part of the
right coronary artery (MRCA) (8 lesions) and middle part of the left circumflex artery (MLCX) (6
lesions). The authors had to cover plaque entirely with SES, so SES implantation usually took longer
than the bare stent (BS). The authors followed the initial clinical outcome of the patients within 1
month after discharge. Few adverse clinical events were found during 1 month follow-up because SES
have a very low rate of restenosis in the short-term so, we have to follow-up the patients over a longer
period and will report the clinical outcome in the next study.
Key word
: Sirolimus Eluting-Stents, Clinical Experience, Outcome, Coronary Artery Disease
Download:
PDF